Zejula, also known by its generic name niraparib, is a medication that belongs to a class of drugs called PARP inhibitors. It is commonly used in the treatment of certain types of ovarian cancer, specifically in patients who have responded well to platinum-based chemotherapy. Zejula works by blocking the activity of an enzyme called PARP, which plays a key role in repairing damaged DNA in cancer cells. By inhibiting this enzyme, Zejula helps to prevent cancer cells from repairing themselves, ultimately leading to their death.

It is important to note that Zejula is not a cure for ovarian cancer, but rather a maintenance therapy that can help to prolong the time before the cancer progresses. This medication is typically taken in the form of a daily oral tablet, and the dosage may vary depending on the individual patient’s needs and medical history.

As with any medication, Zejula can cause side effects, which may include nausea, fatigue, low blood cell counts, and digestive issues. It is important to discuss any potential side effects with your healthcare provider, as they can provide guidance on how to manage them effectively.

If you are considering taking Zejula or have been prescribed this medication, it is crucial to follow your healthcare provider’s instructions carefully and attend all scheduled appointments to monitor your progress. Your healthcare team will work closely with you to ensure that you are receiving the best possible care and support throughout your treatment journey.

Overall, Zejula is a valuable medication in the treatment of ovarian cancer, and it has shown promising results in helping patients to manage their disease and improve their quality of life. If you have any questions or concerns about Zejula, do not hesitate to reach out to your healthcare provider for more information.